C

CASI Pharmaceuticals Inc
NASDAQ:CASI

Watchlist Manager
CASI Pharmaceuticals Inc
NASDAQ:CASI
Watchlist
Price: 1.065 USD 23.26% Market Closed
Market Cap: 16.5m USD

Intrinsic Value

The intrinsic value of one CASI stock under the Base Case scenario is 4.627 USD. Compared to the current market price of 1.065 USD, CASI Pharmaceuticals Inc is Undervalued by 77%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CASI Intrinsic Value
4.627 USD
Undervaluation 77%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation History
CASI Pharmaceuticals Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about CASI?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CASI valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for CASI Pharmaceuticals Inc.

Explain Valuation
Compare CASI to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CASI?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
CASI Pharmaceuticals Inc

Current Assets 18m
Receivables 5.4m
Other Current Assets 12.6m
Non-Current Assets 13m
Long-Term Investments 1.7m
PP&E 10m
Intangibles 230k
Other Non-Current Assets 1.1m
Current Liabilities 38m
Accounts Payable 810k
Accrued Liabilities 18m
Other Current Liabilities 19.2m
Non-Current Liabilities 14m
Other Non-Current Liabilities 14m
Efficiency

Free Cash Flow Analysis
CASI Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
CASI Pharmaceuticals Inc

Revenue
31.6m USD
Cost of Revenue
-13.8m USD
Gross Profit
17.8m USD
Operating Expenses
-60.5m USD
Operating Income
-42.8m USD
Other Expenses
-3.8m USD
Net Income
-46.5m USD
Fundamental Scores

CASI Profitability Score
Profitability Due Diligence

CASI Pharmaceuticals Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
ROE is Increasing
Exceptional Gross Margin
Strong 3Y Average Gross Margin
26/100
Profitability
Score

CASI Pharmaceuticals Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

CASI Solvency Score
Solvency Due Diligence

CASI Pharmaceuticals Inc's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
28/100
Solvency
Score

CASI Pharmaceuticals Inc's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CASI Price Targets Summary
CASI Pharmaceuticals Inc

Wall Street analysts forecast CASI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CASI is 4.08 USD with a low forecast of 4.04 USD and a high forecast of 4.2 USD.

Lowest
Price Target
4.04 USD
279% Upside
Average
Price Target
4.08 USD
283% Upside
Highest
Price Target
4.2 USD
294% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

CASI Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CASI is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one CASI stock?

The intrinsic value of one CASI stock under the Base Case scenario is 4.627 USD.

Is CASI stock undervalued or overvalued?

Compared to the current market price of 1.065 USD, CASI Pharmaceuticals Inc is Undervalued by 77%.

Back to Top